Sartorius Launches Developability and Manufacturability Assessment Service with MAbSilico to Accelerate Therapeutic Protein Lead Candidate Selection

Integrated AI and cell line development workflow aims to reduce manufacturing risks and shorten timelines from sequence design to high-yield production cell lines. Göttingen, Germany — October 5, 2026 — Sartorius, a leading international partner to life sciences research and the biopharmaceutical industry, and France-based MAbSilico, a pioneer TechBio company specializing in AI-based antibody drug